- Home
- AOMR vs CLLS Comparison
AOMR vs CLLS Comparison
Compare AOMR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AOMR | CLLS |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.7M | 384.3M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AOMR | CLLS |
|---|---|---|
| Price | $8.28 | $3.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $11.31 | $8.50 |
| AVG Volume (30 Days) | ★ 67.4K | 48.3K |
| Earning Date | 05-04-2026 | 03-19-2026 |
| Dividend Yield | ★ 15.44% | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.38 | N/A |
| P/E Ratio | $4.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.36 | $1.10 |
| 52 Week High | $10.21 | $5.48 |
Technical Indicators
Market Signals| Indicator | AOMR | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.35 | 42.08 |
| Support Level | $8.18 | $3.32 |
| Resistance Level | $8.91 | $3.83 |
| Average True Range (ATR) | 0.19 | 0.21 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 36.84 | 22.37 |
Price Performance
Historical ComparisonAbout AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.